Navigation Links
Industry Veteran Katrine Bosley Joins Genocea Biosciences' Board Of Directors
Date:3/12/2013

CAMBRIDGE, Mass., March 12, 2013 /PRNewswire/ -- Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has added Katrine Bosley , a proven biotechnology industry leader, as an independent director.

"Katrine brings a unique and important perspective to our board as we continue to advance our lead programs within this new class of vaccines," said Chip Clark , CEO of Genocea. "The breadth of her experience in creating strategic and business development value will be tremendously important as Genocea develops."

Genocea's lead programs include GEN-003, a therapeutic vaccine candidate designed to treat people infected with Herpes Simplex Virus type 2 (HSV-2), and GEN-004, a vaccine candidate to prevent infections caused by Streptococcus pneumoniae. Genocea has fully enrolled its Phase 1/2a study of GEN-003 and expects to report preliminary data in the second half of 2013. The company also anticipates beginning clinical trials in late 2013 for GEN-004.

"Genocea's ability to create T cell-directed vaccines is pioneering and has the potential to significantly extend the range of diseases that can be addressed by vaccines," said Bosley. "The team at Genocea is developing product candidates that tackle tough, important medical problems. This combination of innovation and execution makes Genocea a uniquely exciting company."

Katrine was the CEO of Avila Therapeutics and led the company to establish several strategic alliances prior to its acquisition by Celgene in 2012. Before Avila, Katrine was Vice President, Business Development at Adnexus Therapeutics (acquired by Bristol-Myers Squibb). She joined Adnexus from Biogen Idec where she held roles in business development, commercial operations, and portfolio strategy in the U.S. and Europe and led the in-licensing of Tysabri® (natalizumab) among a number of other transactions. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners.

About Genocea Biosciences
Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify and employ T cell antigens using ATLAS™, its proprietary technology platform, which mimics human T cell immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them.

Genocea's pipeline of novel T cell vaccines includes GEN-003, a clinical-stage program in Herpes Simplex Virus type 2 (HSV-2) therapy, and GEN-004 for Pneumococcus, as well as earlier-stage programs for Chlamydia, HSV-2 prophylaxis, and malaria.

For more information, please visit the company's website at Genocea.com.

For information contact:
Jessica Rowlands
Feinstein Kean Healthcare
202-729-4089
jessica.rowlands@fkhealth.com


'/>"/>
SOURCE Genocea Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rutgers Business Schools Pharma Industry Scholars Program offers students distinct advantages to help boost careers in healthcare industry
2. Frost & Sullivan: Government Support Vital to Encourage Venture Capital Investments in the North American Healthcare Industry
3. DATATRAK Participates in March Industry Events
4. TCS Named as a Leader in Life Science Drug Safety Services by Leading Industry Research Firm
5. HIMMS 2013 - Santa Rosa Holdings Hosts Healthcare Industry Leaders Tommy Thompson and Fred Brown March 5th in New Orleans
6. Medical Marijuana Inc Reviews State of the Industry and Prospects for Future Growth
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
9. Medbox Featured in Huffington Post Report on the Legal Marijuana Industry
10. Promise and Problems Signal Mixed Year Ahead for Biopharmaceutical Industry, Says Pharmaceutical Executive Magazine
11. Global Trends in the Medical Devices Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016   Zillion Group today announced ... platform, which specializes in live video consultation. Turning ... products, Zillion enables companies to realize the true ... take control of their health. ... including one-to-one, group and webcast scheduled or on-demand ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal ... a senior from the University of Florida College ... the Bayer Excellence in Communication Award (BECA). Brittany ... which were awarded a total of $70,000 in ... last four years, Bayer has provided a total ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
Breaking Medicine Technology:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... One way ... say anything.” This is unfortunately true. But we toss the baby out with the ... single-page brief provides tips for identifying higher-quality studies and otherwise making better use of ...
(Date:4/28/2016)... ... April 28, 2016 , ... USA Medical Card reminds us that May is National Stroke ... is the fourth leading cause of death in the United States; someone has one every ... of them in individuals under 65 years old. A stroke is when blood flow ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
(Date:4/28/2016)... ... 28, 2016 , ... A first-time look at workers’ compensation claims in Kentucky ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were stable ... 16th Edition , found that indemnity costs per claim and benefit delivery expenses per ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
Breaking Medicine News(10 mins):